Does Humana Cover Weight Loss Drugs? Honest Coverage Review

Short version: Humana is primarily a Medicare insurer. At the end of 2025, about 8.3 million of its roughly 15 million medical members were in Medicare Advantage or standalone Part D (PDP) plans, and it no longer sells employer-group commercial medical plans. That decides most of the answer. Federal Medicare law keeps drugs “used for… weight loss” out of the Part D benefit, so Wegovy, Zepbound, and Saxenda prescribed for weight loss only are not covered by a Humana Medicare plan, no matter how much medical necessity is documented. The realistic Humana coverage paths are the carve-in indications: GLP-1s for type 2 diabetes (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus), Zepbound for obstructive sleep apnea, and Wegovy for cardiovascular risk reduction or MASH liver disease, each with prior authorization. Since July 1, 2026, a separate CMS program, the Medicare GLP-1 Bridge, offers some Part D members Wegovy, Zepbound, or Foundayo for weight loss at $50 a month, outside Humana's plan.

At a glance

• Humana is a Medicare-first insurer. At year-end 2025, about 5.2 million members were in individual Medicare Advantage, about 0.6 million in group Medicare Advantage, and about 2.5 million in standalone Part D, out of roughly 15 million medical members; the rest were mainly TRICARE (military) and Medicaid.^[15] For most members who get drug coverage from Humana, federal Part D rules drive the answer.
• Weight-loss-only GLP-1s (Wegovy, Zepbound, Saxenda): NOT covered on Humana Medicare plans. Federal law leaves “agents when used for anorexia, weight loss, or weight gain” out of the Part D benefit.^[1] Humana requires a diagnosis code on GLP-1 pharmacy claims, so an obesity-coded claim does not go through.^[14]
• GLP-1s for type 2 diabetes: generally YES with prior authorization. Ozempic, Mounjaro, Trulicity, Victoza, and Rybelsus are coverable on Humana Part D formularies for the T2D indication.^[2][14]
• Zepbound for obstructive sleep apnea: potentially YES with PA. The FDA approved Zepbound for moderate-to-severe OSA in adults with obesity on 12/20/2024, and CMS confirms this use stays a Part D benefit.^[5][11]
• Wegovy for cardiovascular risk reduction or MASH: potentially YES with PA. The FDA approved Wegovy to reduce major adverse cardiovascular events in adults with established CVD plus overweight/obesity on 3/8/2024 (SELECT trial), and the label now also covers noncirrhotic MASH with moderate-to-advanced fibrosis under accelerated approval. Both are Part D-coverable uses.^{[4][8][11][16]}
• Medicare GLP-1 Bridge (live since July 1, 2026): eligible Part D members can get Wegovy (injection or tablet), Zepbound KwikPen, or Foundayo for weight loss at a $50 copay per month, through a CMS demonstration that runs outside the Part D benefit through December 31, 2027.^[6][12]
• No more Humana commercial plans: Humana finished exiting its employer-group commercial medical business, including FEHB plans, during 2025.^[15]
• Humana Medicaid: where Humana runs Medicaid managed care, weight-loss GLP-1 coverage follows the state Medicaid program's drug list.
• Pharmacy benefit: Humana runs its pharmacy benefit in-house, with CenterWell Pharmacy (formerly Humana Pharmacy) and CenterWell Specialty Pharmacy as its mail-order and specialty pharmacies.^[3]

Why Humana is a Medicare-coverage question first

Most write-ups about “does my insurer cover Wegovy” assume a commercial employer plan where the answer turns on the employer's benefit design and the PBM's formulary. Humana is different. Its drug-coverage members are overwhelmingly in Medicare products: Medicare Advantage prescription-drug plans (MA-PD) and standalone Part D drug plans (PDP).^[15] Its other large blocks don't run through a Humana commercial formulary either: Humana Military administers TRICARE East, but the TRICARE pharmacy benefit is run by Express Scripts,^[17] and Humana Medicaid follows state rules. So the first and most important filter is not Humana's discretion at all. It is federal Medicare Part D law.

Section 1860D-2(e)(2)(A) of the Social Security Act removes from the definition of a “covered Part D drug” any drug use that state Medicaid programs may exclude under §1927(d)(2), and that list includes “agents when used for anorexia, weight loss, or weight gain.”^[1] Because weight-loss use is outside the Part D benefit by law, no Part D plan, Humana included, covers anti-obesity medications prescribed for weight loss alone. Humana says so directly in its pharmacy guidance: weight loss is excluded from coverage on its MAPD/PDP plans.^[14] This is not a Humana policy choice that medical-necessity documentation can overturn.

So the structure of the Humana answer is: identify whether you are on a Humana Medicare plan (most members with Humana drug coverage) or a Medicaid plan, then identify the indication the prescription is written for. Indication is what unlocks or blocks coverage on Medicare, not BMI and not how badly you want the drug.

GLP-1 coverage for type 2 diabetes (the widely covered path)

Type 2 diabetes is not a weight-loss indication, so the Part D exclusion does not touch it. Across Humana's MA-PD and PDP formularies, GLP-1 receptor agonists for T2D are generally on-formulary with prior authorization:

• Ozempic (semaglutide) — once-weekly injection, FDA-approved for T2D + cardiovascular risk reduction in T2D with established CVD.
• Mounjaro (tirzepatide) — once-weekly dual GIP/GLP-1, FDA-approved for T2D.
• Trulicity (dulaglutide) — once-weekly GLP-1, FDA-approved for T2D + CV risk reduction.
• Victoza (liraglutide) — daily GLP-1, FDA-approved for T2D; older agent with branded and authorized-generic forms.
• Rybelsus (oral semaglutide) — daily oral tablet, FDA-approved for T2D.

Typical Humana PA criteria for a T2D GLP-1: a confirmed T2D diagnosis (ICD-10 E11.x), a documented A1C, often a trial of metformin (or documented intolerance/contraindication), and prescriber documentation of treatment goals. Since June 1, 2023, Humana has required pharmacies to enter a diagnosis code for a medically accepted indication on every GLP-1 claim, so a claim coded for obesity rather than diabetes is rejected at the point of sale.^[14] For drug-level reference data, see our semaglutide drug page and tirzepatide drug page.

Weight-loss-only GLP-1s on Humana Medicare (excluded)

The FDA-approved anti-obesity GLP-1s — Wegovy (semaglutide), Zepbound (tirzepatide), Saxenda (liraglutide 3.0 mg), and the newer oral Foundayo (orforglipron) — are not covered on a Humana Medicare plan when prescribed for weight loss. The mechanism is concrete: Humana's claims system reads the submitted diagnosis code, and a weight-loss use falls outside the Part D benefit.^[1][14] No prior authorization will overturn it, because PA decides medical necessity within a covered benefit; here the benefit itself excludes the use.

This is the single most important thing for a Humana Medicare member to understand: the barrier is statutory, not clinical. The productive move is not to fight the weight-loss denial but to check whether a different FDA-approved indication applies (OSA, cardiovascular risk reduction, or MASH) or whether you qualify for the CMS Bridge program described below.

The carve-in indications Humana Medicare CAN cover

Three FDA-approved uses that are not weight loss turn the same molecules into coverable Part D drugs. CMS has told Part D plans, Humana included, that they must keep covering these uses and must not deny or limit them in a way that pushes members into the Bridge program.^[11]

• Zepbound for moderate-to-severe obstructive sleep apnea. The FDA approved this indication on December 20, 2024, making Zepbound the first drug approved for OSA in adults with obesity. Because OSA is not a weight-loss indication, a Humana Medicare plan can cover Zepbound for OSA subject to PA, which typically asks for a sleep study confirming moderate-to-severe OSA alongside obesity. The SURMOUNT-OSA trial is the underlying evidence base.^[5][7]
• Wegovy for cardiovascular risk reduction. The FDA approved this indication on March 8, 2024, for adults with established cardiovascular disease and overweight or obesity, based on the SELECT trial.^[4][8] It is coverable on Medicare Part D, though Humana formularies vary in how they tier and PA it.
• Wegovy for MASH. Wegovy's label now includes noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis (F2–F3) in adults, under accelerated approval.^[16] CMS lists MASH among the conditions that are already Part D-coverable.^[11]

Practically: if you have documented moderate-to-severe OSA, established CVD, or diagnosed MASH with moderate-to-advanced fibrosis, the carve-in indication is the realistic Humana path to a GLP-1, and your prescriber should write and code the prescription to that indication, not to weight loss. Confirm tier and PA rules on your specific plan's formulary.

The Medicare GLP-1 Bridge program (live since July 2026)

Separately from the Part D benefit, CMS runs a temporary demonstration called the Medicare GLP-1 Bridge. It began on July 1, 2026 and runs through December 31, 2027. Eligible people with Medicare drug coverage, including Humana MA-PD and PDP members, pay a $50 copay for a one-month supply (28 or 30 days, depending on the drug), at any dose.^[6] Humana describes the program on its own Medicare site.^[2]

• Drugs covered: Foundayo (tablet), Wegovy (injection or tablet), and Zepbound KwikPen only; Zepbound single-dose vials and pens are not included.^[6]
• Eligibility: age 18 or older and, when starting GLP-1 therapy, a BMI of 35 or higher; or a BMI of 30 or higher with heart failure with preserved ejection fraction, uncontrolled high blood pressure, or chronic kidney disease stage 3a or higher; or a BMI of 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease.^[6]
• Who is excluded: people with type 2 diabetes, moderate-to-severe sleep apnea, or MASH (their Part D plan may cover a GLP-1 instead), and people who already get, or in 2026 already got, a GLP-1 through their Part D plan.^[6][11]
• How it works: a single CMS processor handles prior authorization and claims; Humana and other Part D plans are not participants and carry no financial risk. The prescriber must certify the drug is used with a diet-and-exercise program, and an approved PA lasts through December 31, 2027 unless you switch drugs. Participating manufacturers supply the drugs at a net price of $245 per month.^[6][11]
• Cost rules: the $50 copay does not count toward your Part D deductible or out-of-pocket limit, cannot be lowered by Extra Help, and cannot be spread out through the Medicare Prescription Payment Plan.^[6][11]
• What comes next: on April 21, 2026, CMS delayed the Part D portion of the longer-term BALANCE Model for 2027 and extended the Bridge through the end of 2027 instead. CMS has not set a new Part D start date; the Medicaid portion of BALANCE is going ahead in states that join.^[12]

For a Humana Medicare member who wants a weight-loss GLP-1 and has no OSA, CVD, MASH, or diabetes diagnosis, the Bridge is the one covered route, at far less than cash pay. Ask your prescriber to check the criteria and submit the Bridge prior authorization; you can also call 1-800-MEDICARE about eligibility or PA status.^[6]

What the 2027 Medicare negotiated price for semaglutide changes

Under the Medicare Drug Price Negotiation Program, CMS and Novo Nordisk agreed to a negotiated price for Ozempic, Rybelsus, and Wegovy of $274 for a 30-day supply, effective January 1, 2027, compared with a 2024 list price of $959 (a 71% discount). For a 4-pen box of Wegovy 2.4 mg the negotiated price is $385.63.^[13] This lowers what Medicare pays for these drugs when they are covered under Part D, such as Ozempic for diabetes or Wegovy for cardiovascular risk reduction. It does not remove the weight-loss exclusion, so it does not make weight-loss-only Wegovy a Humana Part D benefit. Your copay for a covered use still depends on your plan's tier design.

Humana Medicaid, TRICARE, and the former commercial book

The members who are not in Humana Medicare drug plans fall into a few groups, and none of them gets a Humana commercial weight-loss benefit:

• Former commercial / employer members: Humana finished its exit from employer-group commercial medical plans, including fully insured, self-funded, and Federal Employee Health Benefit plans, during 2025.^[15] If you have employer coverage now, your current insurer's formulary decides AOM coverage.
• Humana Medicaid managed care: where Humana administers a state Medicaid plan, weight-loss GLP-1 coverage follows the state Medicaid drug list. Some states cover AOMs; others exclude them. T2D coverage is generally retained regardless.
• TRICARE East (Humana Military): the TRICARE pharmacy benefit is administered by Express Scripts under TRICARE's own rules, not a Humana formulary.^[17]

How to find out if YOUR Humana plan covers a GLP-1

Four reliable ways, fastest to most authoritative:

1. Humana.com Drug List / formulary search. Sign in, select your specific plan, and search “Wegovy,” “Zepbound,” or “Ozempic.” The result shows the tier, whether prior authorization is required, and any step-therapy or quantity limits.^[2]
2. Phone Humana Member Services / Pharmacy. Use the number on the back of your card and ask specifically: “Is (drug) covered on my plan for (indication)? What is the copay tier, the PA requirement, and the diagnosis code my pharmacy must submit?”
3. Ask your prescriber to run a benefits/PA check. For Medicare members the indication coded on the prescription is decisive; have your prescriber confirm whether you qualify under T2D, OSA, CVD, or MASH, or under the Bridge criteria, before the prescription is sent.
4. Read your Evidence of Coverage (EOC). The EOC is the controlling document for a Medicare plan and lists excluded drugs explicitly.

Prior authorization and appeals on Humana

When the prescription is for a covered indication (T2D, OSA, CVD, or MASH), PA is the gate. The prescriber submits clinical documentation — diagnosis code, supporting labs or sleep study, prior-therapy history — to Humana. If Humana denies, Medicare members have a defined federal appeal pathway, which the Bridge program does not change:^[11]

1. Coverage determination / redetermination. First, request a coverage determination; if denied, file a Level 1 appeal (redetermination) with the plan, typically within 60 days of the denial notice. The prescriber can submit a supporting statement of medical necessity.
2. Independent Review Entity (IRE). If the plan upholds the denial, a Level 2 appeal goes to a CMS-contracted Independent Review Entity that is independent of Humana.
3. Higher Medicare appeal levels. Beyond the IRE, the Medicare appeals process continues to an Administrative Law Judge, the Medicare Appeals Council, and ultimately federal court, with dollar-amount thresholds at the higher levels.

Key point for Humana Medicare members: appealing a weight-loss-only denial will not succeed, because the exclusion is statutory. Appeals are worth pursuing when the denial is on a covered indication (e.g., an OSA or CVD prescription denied on documentation grounds), not when the issue is the weight-loss exclusion itself.

If Humana excludes it — what actually works

Ranked by cost, the practical options if you are on Humana Medicare without a covered indication:

• The Medicare GLP-1 Bridge. If you meet CMS's criteria, this is the cheapest covered weight-loss route at $50 a month for Wegovy, Zepbound KwikPen, or Foundayo, through December 31, 2027.^[6]
• The OSA pathway (Zepbound). If you have a sleep-study-confirmed moderate-to-severe OSA diagnosis plus obesity, your prescriber can submit a Zepbound PA to Humana for the OSA indication.^[5]
• The CVD or MASH pathway (Wegovy). If you have established cardiovascular disease plus overweight/obesity, or MASH with moderate-to-advanced fibrosis, your prescriber can submit a Wegovy PA for that indication.^[4][16]
• Manufacturer self-pay. LillyDirect sells Zepbound vials and KwikPens from $299 a month (2.5 mg), $399 (5 mg), and $449 for higher doses when refilled within 45 days.^[18] Novo Nordisk's self-pay price for Wegovy pens is $349 a month for doses through 2.4 mg, and the Wegovy pill starts at $149 a month.^[19] Cash pay, no insurance involved.
• Compounded tirzepatide or semaglutide via verified 503A telehealth. Typically $149-$349/month. Not brand Wegovy or Zepbound and not FDA-approved; quality and supply-chain rigor vary widely, so diligence matters. To compare reputable telehealth options, see our best semaglutide providers and best tirzepatide providers rankings.

For mechanism-of-action context and the underlying weight-loss magnitudes (STEP-1 semaglutide -14.9% body weight at 68 weeks^[9]; SURMOUNT-1 tirzepatide 15 mg -20.9% at 72 weeks^[10]), plus the broader payer landscape, see our insurance coverage hub.

Verdict — what most Humana members should expect

For the median Humana member asking does Humana cover weight-loss drugs, the answer is shaped by the fact that most Humana members with drug coverage are on Medicare:

1. Weight-loss-only Wegovy/Zepbound/Saxenda on a Humana Medicare plan: NO. Federal law keeps weight-loss drugs out of Part D; no PA or appeal overturns it.
2. GLP-1s for type 2 diabetes (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus): generally YES with PA, on Humana Part D formularies.
3. Zepbound for moderate-to-severe OSA and Wegovy for cardiovascular risk reduction or MASH: potentially YES with PA. These are the realistic Humana carve-in paths.
4. Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027): the covered route to a weight-loss GLP-1 at $50 a month, run by CMS rather than Humana, if you qualify.
5. Humana Medicaid: follows the state's drug list. Humana no longer offers employer-group commercial plans.

The decisive variable on Humana is rarely the formulary tier and almost always the indication and the plan type. Get the indication right (diabetes, OSA, CVD, or MASH), confirm your plan type, and check whether the Bridge criteria fit you. That sequence determines coverage far more than any prior-authorization paperwork.

Further reading

• Does Kaiser Permanente cover weight-loss drugs?
• GLP-1 insurance coverage hub